MODEL MOUSE

摘要

It is intended to provide means for ascertaining the valid effect of molecular target curative medicine per se or used in combination with immunotherapy under nonclinical conditions closely related to human. In particular, the usefulness of antitumor agent acting on EGFR combined with an immunotherapeutic agent can be nonclinically evaluated by establishing an experimental system wherein an EGFR-positive mouse tumor strain is transplanted into a nonimmunodeficient mouse as means for nonclinically ascertaining the attainment of superior synergistic effect of joint use of tyrosine kinase inhibitor and immunotherapy such as IL-12 production inducer on cancer treatment.